eCommons@AKU
Community Health Sciences

Department of Community Health Sciences

5-29-2014

Rationale, design, and cohort enrolment of a prospective
observational study of the clinical performance of the new
contraceptive implant (Femplant) in Pakistan
Syed Khurram Azmat
Waqas Hameed
Anja Lendvay
Babar Tasneem Shaikh
Ghulam Mustafa

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_chs_chs
Part of the Maternal and Child Health Commons, Obstetrics and Gynecology Commons, and the
Women's Health Commons

Authors
Syed Khurram Azmat, Waqas Hameed, Anja Lendvay, Babar Tasneem Shaikh, Ghulam Mustafa,
Muhammad Ahmed Siddiqui, Sajid Brohi, Asif Karim, Muhammad Ishaque, and Wajahat Hussain

International Journal of Women’s Health

Dovepress
open access to scientific and medical research

S t u dy P r o t o c o l

International Journal of Women's Health downloaded from https://www.dovepress.com/ by 58.27.240.66 on 07-Aug-2021
For personal use only.

Open Access Full Text Article

Rationale, design, and cohort enrolment
of a prospective observational study of the clinical
performance of the new contraceptive implant
(Femplant) in Pakistan
This article was published in the following Dove Press journal:
International Journal of Women’s Health
29 May 2014
Number of times this article has been viewed

Syed Khurram Azmat 1
Waqas Hameed 1
Anja Lendvay 2
Babar Tasneem Shaikh 3
Ghulam Mustafa 1
Muhammad Ahmed
Siddiqui 1
Sajid Brohi 1
Asif Karim 1
Muhammad Ishaque 1
Wajahat Hussain 1
Mohsina Bilgrami 1
Paul J Feldblum 2
Research, Monitoring and Evaluation
Department, Marie Stopes Society,
Karachi, Pakistan; 2FHI 360, Durham,
NC, USA; 3Health Services Academy,
Islamabad, Pakistan
1

Introduction: The use of hormonal implants has gained positive traction in family planning
programs in recent times. Compared to other popular methods, such as long-term reversible
intrauterine devices, the use of hormonal implants as a family planning method has distinct
advantages in terms of long-term efficiency and better user compliance and availability. This
paper presents a study protocol to document and evaluate the efficacy, safety, and acceptability
of Femplant (contraceptive implant) in Pakistan during the first year of its use among married
women of reproductive age (18–44 years) at clinics in two provinces of Pakistan (Sindh and
Punjab).
Materials and methods: A total of 724 married women were enrolled in a noncomparative
prospective observational study. The study involved six government clinics from the Population
Welfare Department in Sindh Province and 13 clinics run by the Marie Stopes Society (a local
nongovernmental organization) in both provinces. The participation of women was subject to
voluntary acceptance and medical eligibility. All respondents were interviewed at baseline and
subsequently at each scheduled visit during the study period. Side effects, complications and
adverse events, if any, were recorded for every participant at each visit to the facility.
Discussion: Over the next 5-year period (2013–2018), 27 million hormonal implants will be
made available in lower- to middle-income countries by international donors and agencies.
The evidence generated from this study will identify factors affecting the acceptability and
satisfaction of end users with Femplant (Sino-implant II). This will help to guide policies to
enhance access to and the use of long-acting contraceptive implants in Pakistan and similar
developing countries.
Keywords: safety, efficacy, acceptability, implant, Femplant, contraception, family planning,
Pakistan
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Reversible long-term contraceptive methods (LTCMs), including intrauterine devices
(IUDs) and implants, have a proven record of long-term effectiveness, convenience,
and high user satisfaction.1,2 When compared with short-term methods, hormonal
implants are more reliable, have better efficacy (.99%), are more cost-effective, and
demonstrate high method-continuation rates (80% at 2 years postinsertion).3,4,5–9 Due
to convenient use and better availability, implants are becoming increasingly popular
when used in family planning programs.4
Hormonal implants are considered safe and suitable for nearly all women.10 They
also offer great promise and privacy in helping to meet the needs of younger women,
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who often face social and cultural barriers to accessing effective modern contraception.11
The implants are made of thin, flexible, matchstick-sized
rods of soft plastic.12 The rods contain progestin hormone,
and are surgically placed beneath the skin of a client’s upper
arm by a trained provider, who performs a minor surgical
procedure under local anesthesia to insert or remove the
rods. Implants can be removed whenever a woman wishes
to have them removed, and thus they do not affect the return
to fertility.6
Complications are uncommon, but may include infection
(3%–7%) at insertion sites, difficulties in removal, and rarely
expulsions. The use of hormonal implants is commonly
followed by changes in bleeding patterns including lighter
bleeding, fewer days of bleeding, irregular bleeding lasting more than 8 days, infrequent bleeding, and no monthly
bleeding. About 20%–30% of clients may experience few
other minor side effects, such as headache, abdominal pain,
acne, changes in weight, breast tenderness, dizziness, changes
in mood, and nausea. However, these changes eventually
diminish with time.13,14 Although the acceptability of bleeding
disturbances varies in different cultures, studies have pointed
out that efficacy and safety, factors related to simplicity, ease
of use, acceptability, satisfaction, and contraceptive benefits
can play a role in influencing the adoption of hormonal
methods and determining consistency of use.5,15,16

Context
Of the 208 million unintended pregnancies in 2008, nearly
90% occurred in the developing world.17 In 2012 alone, more
than 220 million women in the developing world had an
unmet need for modern contraception, although this number
had decreased from 226 million in 2008.18 However, the
unmet need for modern contraception in 69 of the world’s
poorest countries has seen an increase of 9 million (from
153 to 162 million women) between 2008 and 2012, and
thus accounts for 73% of all unmet need in the developing
world.18
This high unmet need for contraception, as well as contraceptive failures in the developing world, was responsible
for 80 million unintended pregnancies in 2012. Out of those,
40 million ended in abortions, 30 million in unplanned
births, and the remaining 10 million were terminated as
m iscarriages.18 Access to contraception is low among
women who are poor, less educated, rural, and young (aged
15–24 years).18,19 Almost 99% of maternal deaths occur in
low-resource countries.20 The risk of maternal morbidity
and mortality is higher among poorer women, who have less
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access to modern contraception, including implants.21 Among
the women whose needs for contraception are met, many use
less effective and supply-dependent methods. These include
short-acting methods that require users continually to stock
up their contraceptive supplies, as they do not have access
to highly effective and more convenient long-term methods,
such as implants.11
It is estimated that meeting the unmet need for contraception could reduce maternal mortality by 29% and prevent
more than 100,000 maternal deaths each year globally.22
Additionally, satisfying the unmet need for modern contraception in developing countries would further prevent
54 million unintended pregnancies, including 21 million
unplanned births, 26 million abortions (of which 16 million
would be unsafe), and 7 million miscarriages; this would
also help to prevent 1.1 million infant deaths.18
Globally, 56% of married women aged between 15 and
49 years use a modern method of contraception. However,
the worldwide implant-prevalence rate is extremely low, at
0.3%. Interestingly, very few countries – including some of
the very developed or developing countries – document the
highest implant-use rate in the world, which ranges from
1% to 6%.7 The reasons cited for the low use of implants,
particularly in developing countries, include:
• for clients, the initial high cost of implants compared with
other contraceptive methods;
• for service providers, lack of formal training on insertion
and removal of implant.
The use of implants as an LTCM can be considered
cost-effective provided the discontinuation rate remains low,
one of the reasons for which is lack of formal training on
insertion and removal.5 However, studies have shown that
a huge number of women would choose implants or other
long-term methods if these were available.16
Complications during pregnancy and childbirth remain
the most frequent cause of death for women in Pakistan, as
in other developing countries.23 Each year, around 12,000
maternal deaths occur in Pakistan due to pregnancy-related
complications.24,25 The risk of a woman dying as a result of
pregnancy or childbirth during her lifetime is about one in
4,700 in developed countries.26 In Pakistan, on the other hand,
the risk is about one in 89.23 The high fertility rate of 4.1
children per woman is highest among women who are poor,
uneducated, and live in rural areas. Of every four pregnancies,
one is unplanned. Modern contraceptive use has remained
stagnant at around 30% for over a decade. At 25%, the unmet
need for contraception remains unacceptably high, especially
for women in the lowest income quintile (at 31%), women
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with less education, and women in rural communities. Use
of modern contraceptive methods among currently married
women stands at 22%, and is further lower among women
in rural areas – 17%. Short-term and permanent methods are
the most common contraceptive methods used in Pakistan,
while the use of long-acting and reversible methods like IUDs
and implants is only 2.3% and 0.1%, respectively.23 If only
4% of current oral contraceptive users (100,000 women) in
Pakistan switched to IUDs or implants, it is estimated that
more than 25,000 unintended pregnancies could be averted
over a 5-year period.27
Some studies from developing countries have suggested
that poor screening, insufficient counseling, and health
concerns could be some of the reasons for the lower use
of LTCMs.28,29 However, these studies mainly looked at
determinants of contraceptive uptake, rather than reasons
for continuation or discontinuation. Therefore, a lack of
empirical evidence on LTCMs has been identified as one of
the most important gaps in promoting and increasing their
use in Pakistan.29

The contraceptive method: Femplant
The two-rod subdermal contraceptive implant Sino-implant
(II) (Shanghai Dahua Pharmaceuticals, Shanghai, People’s
Republic of China) is one of the most effective contraceptives
available today.8 It was registered as Femplant in Pakistan in
2010. Like Jadelle® (Bayer, Leverkusen, Germany), another
implant system, the Chinese product contains 150 mg of
levonorgestrel in two rods, and it has an annual pregnancy
risk of lower than 1%. However, the per-unit wholesale cost
of Femplant (approximately US$8) in the year 2010–2011
was considerably lower than the current public sector price of
Jadelle ($21), but in early 2013 Jadelle’s public sector price
dropped to $8.50.31
Femplant is a set of two flexible, cylindrical rods made
of milky-white, medical-grade silicone elastomer. Each rod
contains 75 mg of levonorgestrel, the active ingredient. The
rods are inserted into tubes composed of a colorless, transparent form of silicone elastomer. Both ends of each tube
are sealed with an adhesive. Levonorgestrel, a progestin, is a
synthetic hormone. It mimics progesterone, a potent inhibitor of sex hormones secreted by the pituitary gland. Like
progesterone, levonorgestrel suppresses ovulation. It also
thickens cervical mucus, which impedes the migration of
sperm. Femplant is indicated for women of childbearing age
who wish to use an LTCM.
The two Femplant contraceptive rods are usually inserted
during the first week of a woman’s menstrual cycle (starting
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from the first day of menstruation), or at any other time
when it is reasonably certain that the woman is not pregnant.
A 0.2 cm-long incision is made in the skin of the upper
arm or in the inside of the thigh, and the rods are implanted
beneath the skin with a trocar (surgical instrument) under
local anesthesia and aseptic conditions. An adhesive bandage
is applied to cover the surface of the incision, and then the
limb is wrapped with gauze.
Femplant provides effective contraception for at least
4 years. Medical contraindications include current (history
of) breast cancer; severe liver disease; acute deep venous
thrombosis or pulmonary embolism; unexplained vaginal
bleeding; lactation during the first 6 weeks postpartum;
and systemic lupus erythematous with positive or unknown
antiphospholipid antibodies.10
The adverse effects of Femplant are similar to other
levonorgestrel-releasing implants (eg, Jadelle, Norplant).
The vast majority of levonorgestrel-implant users experience
menstrual problems, but serious bleeding problems are not
more frequent than in controls. Other adverse events (AEs)
may include skin conditions, headaches, dizziness, nervousness, weight change, anxiety, and nonclinical depression.
Most of these side effects are mild, and normally resolve
spontaneously after several months of use. More serious AEs
(ie, hypertension, gallbladder disease) are rare.29
For over 50 years, progesterone has been used in the
treatment of recurrent endometrial cancer in the form of
pills, injections, implants, and long-acting progestin IUDs,
which are also known as the levonorgestrel intrauterine
system (LNG-IUS). This LNG-IUS is used especially in
breast cancer patients taking tamoxifen (TAM) to prevent
endometrial proliferation. A recent systematic review, though,
concluded that there was no significant relationship between
breast cancer and the use of long-acting progestin-releasing
devices, such as LNG-IUS, but still unclear about the possible effects of Mirena® (Bayer) or LNG-IUS on the breast.
Therefore, the use of any long-acting progestin-only device,
whether for an IUS/IUD or implant, requires both caution and
more detailed clinical evidence for decision making, which
right now is limited.30

Rationale for the study
The contraceptive effectiveness and safety of Sino-implant
(II) was evaluated in 15 clinical trials, all conducted in the
People’s Republic of China.14 Outside these clinical trial settings, more than 7 million units of Sino-implant (II) have
been distributed, mainly in the People’s Republic of China
and Indonesia. Although the documented clinical experience
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with Sino-implant (II) outside these Asian countries is limited,
preliminary data (during the first of year of use) from a study
conducted in Madagascar in 2012 documented promising levels
of safety, effectiveness, and acceptability of Sino-implant (II).31
Therefore, the findings of this study will contribute to the body
of knowledge on the clinical performance of Femplant outside
the People’s Republic of China, Indonesia, and Madagascar.

Study partners
The Marie Stopes Society (MSS) is one of the leading
nongovernmental organizations in Pakistan, and has been
providing a full range of high-quality family planning and
reproductive health services to save and improve women’s lives.
The MSS is part of the Marie Stopes International (MSI) global
partnership, committed to and recognized for the highest clinical
and operational standards. FHI 360, with support from the Bill
and Melinda Gates Foundation, provided technical assistance
to facilitate the introduction of Sino-implant (II) (registered by
the MSS in Pakistan as Femplant) – a low-cost, highly effective
contraceptive implant – in resource-constrained countries. With
funding from the US Agency for International Development,
FHI 360 entered into a partnership with the MSS, and provided
financial and technical assistance to implement the prospective
cohort study with the aim of assessing Femplant safety, effectiveness, and acceptability in Pakistan. Engender Health has also
implemented a prospective cohort study in Bangladesh.

Study objective
This study aimed to evaluate the contraceptive effectiveness,
safety, and acceptability of Femplant during the first year of
its use in Pakistan. Specific objectives were to conduct the
postapproval monitoring of:
• the contraceptive effectiveness of Femplant during the
first year of use
• safety of Femplant during the first year of use
• side effects and complications during Femplant insertion
or removal
• acceptability of Femplant during the first year of use
• women’s satisfaction with Femplant services.

Study design
This was a noncomparative prospective observational study
of women using Femplant as a primary method of contraception in the two most populous provinces of Pakistan – Sindh
and Punjab. The provinces were selected on the basis of high
levels of population concentration, similar sociodemographic
characteristics, and relatively better law-and-order situa-
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tions compared with other provinces. Overall, the study was
conducted in a total of 19 clinics, including six government
clinics from the Population Welfare Department (PWD)
in Sindh, and 13 clinics run by the MSS nongovernmental
organization in both provinces. These clinics had sufficient
expected client flow per month and were geographically
(urban- or periurban-based) accessible, facilitating enrollment and follow-up of women in the prospective study.
A total of 724 women, divided into two cohorts, were
enrolled in this 1-year prospective study, comprising:
• a prospective cohort consisting of 392 women who were
followed up at 3 and 12 months after enrolment
• a surveillance cohort of 332 women who returned to the
clinic within 12 months after enrollment if they experienced complications, medical problems, pregnancy, or
wanted to remove the Femplant.
Originally 600 women were supposed to be enrolled but
during the course of study enrollment, there were 124 overenrollments. This overenrollment was communicated to the
Pakistani and FHI 360 institutional review boards (IRBs).
Prior to initiation of the study, we randomly designated clinics to enroll women into either the prospective
or surveillance cohorts. Women were recruited into the
study during their routine family planning visit at either
the participating government-run or MSS clinic. During
the initial visit after the woman had selected to use the
Femplant as her contraceptive method, research staff introduced and explained the study objectives and procedures
and potential risks and benefits of participation. Women
who agreed to participate in the study were asked to sign a
consent form documenting their voluntary decision to join
the study. After signing the informed consent form, each
potential participant was evaluated for medical eligibility
and admitted into the prospective or surveillance cohort,
depending on which arm the clinic had been allocated to.
Women in the prospective cohort were asked to return to
the clinic both 3 and 12 months after the Femplant insertion
to be interviewed and evaluated for pregnancy, AEs, and
method acceptability. Women in both cohorts were encouraged to return to the clinic at any time if they experienced
medical problems or other problems related to the implant,
or became (or suspected that they might be) pregnant, or if
they wanted to remove the implant.

Study population and inclusion criteria
Married women of reproductive age (MWRA) were qualified to participate in the study. To be eligible for inclusion,
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women had to be between 18 and 44 years of age, inclusive.
They must have chosen to use Femplant for contraception,
be medically eligible for this method of contraception, and
give informed consent.

Sample size/sampling strategy
The sample estimation was based on the following
assumption: if we enroll 300 women and assume that loss
to follow-up at 12 months is less than 20% and the true
12-month cumulative probability of pregnancy is no more
than 1%, then we will have a 90% chance of both ruling
out a 4.5% pregnancy probability (ie, obtaining an upper
95% confidence bound of less than 4.5%) and obtaining
an estimated 1-year pregnancy probability of less than 2%.
Our assumptions of the first-year probability of pregnancy
were based on data from the four randomized trials with a
total of 15,943 women assigned to Sino-implant (II) that
showed first-year probabilities of pregnancy ranging from
0.0% to 0.1%.8

Timeline
The overall duration of this study was about 26 months: from
October 2010 to January 2013. The first 5 months comprised
writing the study protocol, developing study instruments and
securing ethical approval from the IRBs from FHI 360 and
Pakistan. The field component consisted of recruitment, and
follow-up took about 16 months. Data entry, analyses, and
report writing were carried out in the final 4 months.

Study setup, visits, and procedures
Admission

Once enrolled in the study and after the implant was inserted
(as described earlier), all women underwent the baseline
interview. After the baseline interview, all MWRA in the
prospective cohort were asked to return to the clinic both 3
months and 12 months after the insertion to be interviewed for
complications, AEs, and acceptability, and to be evaluated for
pregnancy. Women in both cohorts were asked to contact or
return to the clinic if they experienced any medical problems
or pregnancy while using the implant, or if they wanted to
remove the implant.

Visits at 3rd and 12th month
During each follow-up visit, a research nurse conducted the
follow-up interview and completed the appropriate casereport form (CRF). A pregnancy test was administered at
the month 3 visit, only if clinically indicated (eg, absence of
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menses for more than 6 weeks, other signs and symptoms of
pregnancy, or woman’s concern that she may be pregnant),
and in all women at the month 12 visit. Pregnant women
were provided with counseling regarding their pregnancy
options, implant removal, and prenatal care. If the woman
wanted to or already had removed the Femplant, she was
provided with family planning counseling as part of the
standard of care. All efforts were made to contact women
in person through phone calls on the numbers provided by
them or approaching them through persons who had referred
them to the study clinics.

Unscheduled visits
During unscheduled visits, regular follow-up procedures
were followed and study CRFs completed, if appropriate.
Where personal contact was not possible, the follow-up
interview was conducted via phone. All women were encouraged to seek medical care in the clinics where the implant
was inserted or elsewhere if they experienced any medical
problems or suspected that they may be pregnant after the
study was over.

Retention
Measures to improve retention
The study staff emphasized to each participant the importance of follow-up for the entire study period and the need
to return for the follow-up visits. As mentioned earlier,
participants were compensated for their transportation
costs and time to attend the scheduled visits for an amount
approved by the participating IRBs. Clinic staff collected
contact information for each participant. If a participant
missed a scheduled appointment, the clinic staff tried to
locate her using all possible means (eg, telephone, mail
contact, through referees, or possibly in person) and documented these attempts (at least three attempts were made).
The study staff also collected contact information from each
participant for a contact person who would know where
the participant might be. With participants’ consent, these
people were to be contacted in case the participant could
not otherwise be found.
Study outcomes were:
• with the Femplant in place, the cumulative probability
of pregnancy through 1 year
• prevalence and incidence rates of immediate and delayed
complications associated with insertion or removal of the
Femplant
• incidence rate of AEs related to use of the Femplant
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• cumulative probability of early discontinuation of the
Femplant through 1 year
• reasons for discontinuation of Femplant
• level of women’s satisfaction with Femplant services.

more details on collecting safety data). The staff ensured that
all safety information was documented on the follow-up and
SAE forms, if appropriate.

Measurement of acceptability and continuation
International Journal of Women's Health downloaded from https://www.dovepress.com/ by 58.27.240.66 on 07-Aug-2021
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Measurement of study outcomes
For 392 women enrolled in the prospective cohort, data
related to satisfaction with MSS services, pregnancy, AEs,
insertion complications, and acceptability information
were collected through interviews and review of medical
records during admission, follow-up at months 3 and 12,
and during unscheduled visits. This information was documented on the corresponding CRFs. In addition, for another
332 women enrolled in the surveillance cohort, data related
to the main study outcomes were collected through an
interview during unscheduled visits and documented on the
corresponding CRFs.

Measurement of pregnancies
A rapid urine pregnancy test (available through the
MSS in Pakistan) was performed during the month 3 or
unscheduled visits, only if clinically indicated. At the
month 12 visit, a pregnancy test was performed in all 392
participants from the prospective cohort. The study staff
ensured that information about all study pregnancies was
documented on the follow-up and pregnancy-outcome
forms accordingly. Whenever possible, date of conception
was estimated based on the available information (date of
last menses, etc). Pregnancies diagnosed elsewhere (ie,
without confirmation in the study clinic) were considered
study pregnancies.

Measurement of insertion/removal complications
The study staff reviewed the existing medical records for
immediate insertion complications during the admission
visit and documented it on the baseline form. All information
related to delayed complications of the insertion procedure
was collected during the month 3 or unscheduled visits, and
documented on the follow-up form and serious AE (SAE)
form, if appropriate. All complications related to removal
(if occurring during the study) were documented on the
follow-up and SAE forms, if appropriate.

Measurement of adverse experiences
Research staff collected information on all SAEs and bleeding problems that women reported during the month 3,
month 12, or unscheduled visits (see the Safety section for
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Acceptability was evaluated based on continuation rates
and reasons for discontinuation. It was also measured by
responses to the acceptability questions during the follow-up
interviews at the month 3, month 12, or unscheduled visits.
In addition, information on acceptability and continuation
was extracted from the existing records. The research staff
made sure that all relevant acceptability information was
documented on the follow-up form.

Measurement of women’s satisfaction
with Femplant services
Information concerning women’s satisfaction with Femplant
services was measured by responses provided during baseline
interviews and during the admission visit, and documented
on the baseline form.

Completion of the study
A participant was considered to have completed the
study:
• in the prospective cohort – after she had completed her
month 12 follow-up visit, and after her final set of data
had been collected and entered on the appropriate study
CRFs
• in the surveillance cohort – after the 12-month follow-up
of the prospective cohort had been completed and all data
had been entered on the study CRFs
• in both cohorts – after she had become pregnant while
using Femplant.

Loss to follow-up
If a participant in the prospective cohort did not have
any indication that the implant was removed and failed
to appear for the scheduled 3- and/or 12-month visit, she
was presumed lost to follow-up. Study files of participating MWRA who missed their appointments were kept
open until study close in case they returned later for
follow-up. If the participant did not return to the clinic
before the study closed, the follow-up form (namely, the
final status question) was completed at the time of study
close. The form would indicate that the participant was
lost to follow-up; this designation was not made for any
participant until the closing date of the study. “Lost to
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Study discontinuation
Participants were informed that they could withdraw from
the study at any time, for any reason, without loss of other
benefits or services to which they were entitled. We would
discontinue participants from the study if any of the following occurred:
• investigator or other physician decided that continued
participation in the study would be harmful
• study was terminated, and/or other administrative
reasons
• participant decided to or had already removed the
implant
• participant decided to withdraw her participation in the
study.
The study staff documented the reasons for early discontinuation of the Femplant on the follow-up form. Even
when early discontinuation from the study occurred, the staff
made reasonable efforts to collect and assess information
relevant to the study outcomes at the time of discontinuation.
We did not replace any discontinued or lost-to-follow-up
participants.

Safety
Scope of safety data
An AE was any unfavorable and unintended sign, symptom,
or disease temporally associated with the use of a study
product, whether or not this was considered to be related to
the product. Preexisting conditions were not considered AEs
unless they increased in frequency or severity or changed
in nature.
In this study, during both scheduled and unscheduled
visits, we collected information on the following:
• SAEs
• immediate and delayed insertion complications
• immediate and delayed removal complications
• vaginal bleeding problems.
Operational definitions
An SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution.
An SAE included any adverse experience resulting in any of
the following outcomes:
• death
• a life-threatening adverse drug experience
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• inpatient hospitalization (including overnight stay) or
prolongation of existing hospitalization
• a persistent or significant disability/incapacity
• a congenital anomaly/birth.
All reported SAEs (other than insertion complications)
were graded for severity as follows:
• mild (participant was aware of the AE all of the time, but
was still able to do all activities)
• moderate (participant had to discontinue some activities
due to the AE)
• severe (participant was incapacitated by the AE and
unable to perform normal activities).
All reported SAEs were graded for relatedness to the
Femplant as follows:
• unrelated (onset of the AE had no reasonable temporal
relationship to administration of the study product, or
causal relationship to administration of the study product
was biologically implausible, or the event was attributed
to an alternative etiology)
• possibly related (onset of the AE had a reasonable temporal relationship to study-product administration, and
a causal relationship was not biologically implausible)
• definitely related (onset of the AE showed a distinct
temporal relationship to administration of the study
product, or the AE was a known reaction to the product
or chemical group or could be predicted by the product’s
pharmacology).
All immediate and delayed insertion and removal complications were graded for severity as follows:
• mild (did not require any medical intervention)
• moderate (only required resting or minimum level of
medical intervention, such as taking pain medication)
• severe (required attention from medical personnel to
conduct a medical intervention).

Documentation and reporting of safety data
All SAEs in this study were documented on the follow-up
and SAE forms and reported to FHI 360 using the SAE report
form within 24 hours of the study site becoming aware of the
problem, and if required to the local regulatory authorities
and IRB, according to their policies. FHI 360 would report
all SAEs in this study to FHI 360’s Protection of Human
Participants Committee (PHSC), according to FHI 360’s
standard operating procedures.
All insertion and removal complications, as well as bleeding
problems, were documented on the follow-up form. If any
of these medical problems met the definition of an SAE, the
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SAE form would have to be completed. For all SAEs related to
bleeding problems or removal that occurred during the study,
the standard SAE-reporting requirements were followed. Since
the insertion was not part of this prospective study, SAEs related
to the insertion would not be reported to FHI 360, but might
be reported by the MSS to the regulatory authorities or local
pharmacovigilance program in Pakistan as appropriate.
Pregnancy was a study outcome, and was not documented as an adverse experience. Information related to all
study pregnancies was documented on the follow-up and
pregnancy-outcome forms.

Analysis plan
Social harm events
A social harm event was defined as an adverse social consequence or outcome due to study participation. If the site
principal investigator (PI) learned of a social harm event,
he/she would report the event on the social harm event form
to FHI 360 and the IRB within 3 days of becoming aware
of the event.

Data management
A detailed data-management plan was outlined prior to initiation of the prospective study. The following is a brief summary
of the plan. Study research assistants captured data obtained
during the follow-up interview or transcribed the data extracted
from the existing medical records on a two-ply paper CRF. The
original copy was kept in the participant’s original file folder at
the site for monitoring purposes, and the other copy was sent
to the MSS local office for double data entry using EpiData
version 3.1 (EpiData Association, Odense, Denmark).
The electronic datasets were available for interim and
final review and analysis to the research staff at MSI and
FHI 360. Details of data ownership and sharing between
MSI and FHI 360 were specified in the final version of the
data-management plan.

Monitoring plan
A study coordinator worked with the study nurse at each site
and regularly monitored whether the study protocol, datacollection process, and questionnaires were being properly
followed. The following were monitored:
• any changes in the protocol that had been reported to
the head of the Research, Monitoring and Evaluation
Department at the MSS and subsequently to the MSI
project manager
• whether participants’ records were complete and
accurate
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• a log with participants’ names, addresses, clinic file
numbers, and study participant numbers in a confidential
location
• whether the study service-inventory log was current and
showed the total number of procedures carried out
• whether any SAEs were being promptly documented and
reported
• whether physicians and other study staff were carrying out their activities as agreed upon prior to study
initiation.
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A draft analysis plan was developed by FHI 360 and MSI
prior to the initiation of the study. The following is a summary
of the planned analysis. For the 392 women enrolled in the
prospective cohort of this study, all information related to the
study outcomes obtained through the follow-up interview was
documented on the study CRFs. In addition, all information
related to the main study outcomes for the other 332 women
enrolled in the surveillance cohort was extracted from existing medical records or obtained during unscheduled contacts
and visits, documented in the study CRFs, and included in
the final analysis.
Descriptive statistics were used to analyze demographic and baseline characteristics. We used measures of
central tendency and dispersion for continuous variables,
including means, medians, standard deviation, and range.
Categorical data were summarized with frequencies and
percentages.
All SAEs reported during the study were supposed to be
summarized in frequency tables (including both the number
of each type of SAE and the number of distinct participants
with each type of SAE); however, none had been reported
at the completion of the study. Prevalence and incidence
rates were calculated for immediate or delayed complications associated with insertion and/or removal. Rates of
early discontinuations of the Femplant were computed, and
reasons for discontinuation were summarized and presented
in a tabular format. The 1-year cumulative probability of
pregnancy and corresponding 95% confidence interval were
computed using life-table methods, recording women at the
time of implant removal or at the time of their last clinic visit,
whichever came first. Women with no clinical indication of
pregnancy (and hence no pregnancy test) were considered
not to be pregnant through the time of their last clinic visit.
Bleeding problems and rates were computed and presented
in a tabular format.
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Potential risks and benefits
Potential benefits to participants
This study had no expected direct benefits to participants.
However, the findings from this study should generate additional knowledge on the clinical performance of the Femplant
and will benefit potential users of this method in the future.
Participation in the study did not affect fees, payment, billing, or reimbursement for any other services at the clinic.
Participants were, however, compensated for their time and
trouble in completing the month 3 and month 12 visits in
the amount of Rs250 per participant per visit (equivalent
of ∼US$2.30).
Potential risks to participants
All possible efforts were made to prevent loss of confidentiality during the study. Participation in this study had no
other expected risks to participants. All women participating
in this study had personally and voluntarily chosen to use
the Femplant for contraception before they were invited to
participate in this prospective study. Study participants might
have experienced certain side effects, including minimal
risk of pregnancy, but these risks might have been due to
use of the Femplant and not due to their participation in
this study.
We had not anticipated any social harm events for participants during the study, and no social harm event was
reported during the course of the study. Despite that, we
carefully monitored and intended to act accordingly if there
was any unacceptable risk of social harm events resulting
from participation in the study.

Ethical considerations
Institutional review boards
All investigators and research staff involved in the study had
a commitment to respecting the ethical principles of clinical
research. The study protocol, the informed consent form, and
other appropriate documentation were reviewed and approved
as required by the PHSC at FHI 360 (FWA00016827).
The study also received full clearance from the Ethics
Review Committee of the National Bioethics Committee of
the government of Pakistan, reference number 4-8711/NBC/65/RDC/386. The study is also archived at http://apps.who.
int/trialsearch/trial.aspx?trialid=NCT01463254.
Participating research staff were also trained in research
ethics. The PI at the research site was responsible for
ensuring that all requirements of the local IRB were met.
Before implementing any changes to the protocol, informed
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c onsent, advertising, or written materials for participants, the
site PI made sure that all of the changes were approved by
FHI 360’s PHSC and the local IRB, except where necessary
to eliminate immediate hazards to human participants. The
PI was also responsible for notifying FHI 360 and MSI as
soon as possible, after no more than 48 hours, if the local
IRB withdrew its approval of this research at any time before
its completion.
The site PI was also responsible for making progress
reports to the local IRB and to FHI 360 and MSI annually
and within 3 months of study termination or completion.
These reports could include the total number of participants
enrolled, the numbers and reason(s) for discontinuation,
a description of all SAEs, the number of participants completing the study, all changes in the research activity, and all
unanticipated problems involving risks to human participants
or others. Copies of all study-related correspondence with
the local IRB were also sent to FHI 360 and MSI.
Informed consent
The study staff explained the study and its associated procedures, risks, and benefits to the participants. The consent
form was read verbatim to each participant. Each eligible
participant was asked to sign the informed consent form
if she wished to participate in the study. The consent form
was written to be understandable for a 14-year-old (grade 8
reading level). The informed consent document was translated from English into the local Urdu language. It was made
sure that each participant agreed to and understood the risks
and benefits associated with her participation in this study, her
rights to terminate participation in the study without affecting
her health care at the site, whom to contact with questions
regarding the study, and that she had freely given informed
consent to participate in the study and to have her existing
medical records related to the use of the Femplant reviewed
and analyzed as part of the study. A friend/relative accompanying the woman or a clinic staff member not involved in
implementing the study signed the informed consent form to
confirm witnessing the agreement to participate in the study
for all illiterate participants.
Due to the long-term nature of the implant and possible
extension of the follow-up period of the study, all women
were informed of the possibility of more annual follow-up
contacts and asked for their permission to be contacted in
the future. A copy of the signed informed consent form was
also given to the consenting women. Therefore, the signed
informed consent form became a permanent part of the
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participant’s study records. It was stored separately from
other participants’ records related to the study to protect their
confidentiality.
Participants’ confidentiality
Except as required by law, all study staff were committed to protecting the confidentiality of participants to the
fullest extent in order to protect their rights and welfare.
Participants’ contact information and informed consent
documents with names were stored separately from the study
CRFs. No participant’s personal identifiers appeared on any
data or documentation sent to MSI or FHI 360. Participants
were not identified by name in any report or publication
resulting from the study data. Risk of loss of confidentiality
might have occurred if these procedures were inadvertently
breached. All possible efforts were made to prevent this
from happening. The PI at the site permitted trial-related
monitoring, audits, IRB review, and regulatory inspections
by providing direct access to source data and other studyrelated documentation.

Report writing and dissemination plan
The FHI 360 and MSI research teams, working in close collaboration, will determine a detailed data-analysis strategy and
final report outlines, and describe it in the data-management
and analysis plans prior to conclusion of the data collection.
FHI 360 will perform analyses as specified in the analysis
plan and draft a final report based on the data. A publication
is planned following completion of the study.

Discussion
The research evidence from this study will help to identify
factors affecting the acceptability of and users’ satisfaction
with the Femplant (ie, Sino-implant [II]), and help to enhance
access to and use of long-acting contraceptive implants in
Pakistan and similar developing countries. The need for such
research evidence has become more pertinent since international donors, including Bayer and the World Health Organization, joined forces to make 27 million implants available in
resource-constrained countries from 2013 to 2018.32 Further,
there is a dearth of evidence available on the effectiveness
and safety of this method outside the People’s Republic of
China and Indonesia. Therefore, more specifically, the findings of this study will contribute to the body of knowledge on
clinical performance in Pakistan, which will provide timely
recommendations for the successful introduction/marketing
of this new LTCM in the country. Further, this new implant
will fill the gap of need for a reliable and quality LTCM in
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the wake of PDHS findings of a fertility rate of 4.1 children
per woman and only 0.1% of current implant use.23
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